Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7739376 | 0.86 | MMP8 (0.47) | KMT2AMEN1TSHRSLC6A3 | |
| SCHEMBL20411541 | 0.85 | PBRM1 (0.48) | KMT2APBRM1CYP2C19ALDH1A1 | |
| SCHEMBL5643025 | 0.81 | KMT2A (0.53) | KMT2APBRM1PTGS1PTGS2CTSS | |
| SCHEMBL16732180 | 0.80 | KMT2A (0.56) | KMT2APTGS1PTGS2CYP3A4CYP2C19 | |
| SCHEMBL13239389 | 0.78 | KMT2A (0.53) | KMT2APTGS1PTGS2CYP3A4CYP2C19 | |
| SCHEMBL16732226 | 0.78 | KMT2A (0.53) | KMT2APTGS1PTGS2CYP3A4CYP2C19 | |
| SCHEMBL7109702 | 0.76 | KMT2A (0.66) | KMT2APTGS1PTGS2CYP3A4MEN1 | |
| SCHEMBL10448370 | 0.76 | KMT2A (0.66) | KMT2APTGS1PTGS2CYP3A4MEN1 | |
| SCHEMBL11357210 | 0.76 | MMP8 (0.46) | KMT2AMEN1TSHRALDH1A1SLC6A3 | |
| SCHEMBL18264194 | 0.74 | PBRM1 (0.52) | PBRM1PTGS1PTGS2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20050101787-A1 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1512678-A1 | Process for preparing optically active nitro compounds and cyano compounds | Kanto Kagaku Kabushiki Kaisha (JP) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101787-A1 | Process for preparing optically active nitro compounds and cyano compounds | NOS1, NOS2, NOX1 | KMT2A 2915/4885PBRM1 2430/4885PTGS1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.